TrialThe oncologist2015

U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy.

Erin Larkins et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.